Dr. Anjali Pandey has led medicinal chemistry at Sudo Biosciences since its founding in 2020. She is an executive biopharmaceutical R&D leader with 25+ years of experience and expertise in all stages of discovery and development from initial lead identification through approval.

Previously, Anjali was head of medicinal chemistry at Lengo Therapeutics (acquired by Blueprint Medicines Dec 2021) from April 2020 – March 2022. At Lengo Therapeutics, she led the discovery of first-in-human Phase 1/2 clinical candidate LNG-451 (BLU-451). Prior to her role at Lengo, Anjali was CSO/EVP for BridgeBio Pharma oncology companies TheRas Inc., Ferro Therapeutics and Navire Pharma. Prior to that, she spent 14 years at Portola Pharmaceuticals as SVP of Medicinal Chemistry & Chemical Development, where she managed discovery and chemistry, manufacturing and control (CMC) function for Bevyxxa™, Cerdulatinib and all the other small molecule programs. She has been a significant contributor towards the discovery, development and IND-ready and/or 1st in human study for 15 compounds. Dr. Pandey has published 45+ scientific publications and is an inventor on over 70 issued U.S. patents.

Anjali received her M.S. from the Indian Institute of Technology, Kanpur and a Ph.D. from Southern Illinois University and completed her postdoctoral fellowship at SRI International.